Tristel Regulatory News (TSTL)

3 Apr 2008 07:00

Tristel PLC03 April 2008 Tristel plc ("Tristel" or "the Company") Board Appointment Tristel plc, the AIM listed provider of infection and contamination controlproducts, announces the appointment of Mr Bruce Green as a non-executivedirector to the Board with immediate effect. Mr Green, aged 63, has acted as a consultant to Tristel since the incorporationof the Company in 1993. He is the original inventor/pioneer of Tristel'sproprietary chlorine dioxide technology and signed over the patents to Tristelat its admission to AIM in June 2005. Mr Green is currently interested in 864,016 Ordinary 1p Shares, representing 3.2per cent. of the Company' issued share capital. Mr Green is a Chartered Scientist, a Chartered Chemist and a member of the RoyalSociety of Chemistry. For the last 25 years Mr Green has acted as an independentconsultant and formulator in the infection control, cosmetics and food hygieneindustries. Pursuant to Rule 17, Schedule Two (g) of the AIM Rules for Companies thefollowing information is disclosed: Current Appointments Bruce Green LimitedFood Safe Sales LimitedFood Safe Limited (dormant)Floraceuticals Limited (dormant)Toby Brown Limited (dormant)Browns Cosmetics Limited (dormant)Browns Haircare Limited (dormant) Previous Appointments Hairology LimitedClaremont & May of Canterbury LimitedBoxercise LimitedRugby Polo Club LimitedManufacturing Packaging Services LimitedHealth and Hygiene International LimitedFormulas To Go LimitedFirst Rung HousingAqua Safe Technology LimitedThe Real Soil Associates Limited Mr Green was a Director of Janda Chemicals Limited at the time of itsliquidation, following the non payment of monies due from a creditor to JandaChemicals Limited. There is no further information to disclose. Tristel plcPaul Swinney, Chief Executive Tel: 01638 721 500 Daniel Stewart & Company PlcGraham Webster Tel: 020 7776 6576 Parkgreen Communications Ltd Tel: 020 7851 7480Lucy Lake Mob: 07894 263 046 lucy.lake@parkgreenmedia.com Notes to Editors Tristel's core business is the marketing of its proprietary chlorine dioxidechemistry that is highly effective in destroying all types of bacteria(including C difficile, MRSA, bacterial spores, and tuberculosis), fungi andviruses and is one of a small group of sporicidal agents that is safe and easyto use. Tristel plc operates with two divisions, Tristel Solutions and TristelTechnologies. Tristel Solutions focuses on infection control products for NHS and privatesector hospitals, primary care trusts, community hospitals, private practices,dental practices and veterinary establishments. The Company's products are usedon instruments, surfaces, and the skin in over 375 UK hospitals, representingsome 60 per cent of all UK NHS Acute & Private Hospitals. Tristel Technologies provides products for Legionella infection control inbuilding water systems and for contamination control in the food growing andfood processing industries. Tristel Technologies has approximately 200 customersin the government, municipal, industrial, healthcare and food sectors and more40 UK hospitals where its products are used for Legionella control. This information is provided by RNS The company news service from the London Stock Exchange